CEL-SCI Corp (AMEX:CVM)
| CAPS Rating |
|
|---|---|
| Open | $0.42 |
| Previous Close | $0.43 |
| Daily Range | $0.38 - $0.42 |
| 52-Week Range | $0.27 - $0.76 |
| Market Cap | $85.00M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 10,268,493 |
| Average Daily Volume | 0 |
CVM
VS S&P 500 (SPY)
This ticker is not currently Ratable.
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
CVM Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
CVM News and Commentary
- CVM redux – Blog at The Motley Fool
- One Biotech Stock to Avoid – The Motley Fool
- Is Oncothyreon the Perfect Stock? – The Motley Fool
- 4 Immunotherapies to Watch – The Motley Fool
- An Inside Look at Biotech Investing, Part 2 – The Motley Fool
- CEL-SCI Investors Cheer a Bit Too Loudly – The Motley Fool
- Healthcare Headlines: Santarus Rallies, Amgen Announces Results – SeekingAlpha
- Cancer Immunotherapy Index- 116% Annualized Returns- MNTR – Blog at The Motley Fool
- A Strategy for All Situations – The Motley Fool
- A Big Upgrade for Rodman & Renshaw – The Motley Fool
- The Best Stocks for the Next 4 Years – The Motley Fool
- 5 Stocks Bucking the Downtrend – The Motley Fool
- CVM Poised for a rally? – Blog at The Motley Fool
- Cel-Sci has a 3000 Percent Increase Potential – Blog at The Motley Fool
Related News and Articles
- Illuminating the Way Forward for Genomics – The Motley Fool
- When Passing Your Clinical Trial Isn't Enough – The Motley Fool
- This Just In: More Upgrades and Downgrades – The Motley Fool
- Life Technologies' Sequence of Success – The Motley Fool
RSS Headlines
Fool UK
